Aside from these technical issues, some patients with extensive bone involvement could have a negative result on 18F-FDG PET/CT because myeloma cells might have low expression of hexokinase-2, which is involved in the glycolysis of FDG in malignant cells [29]. Here, HK2 is linked to plasma cell myeloma.